Solid tumor/s
CMPXCompass TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for CTX-10726 (PD-1 x VEGF-A bispecific antibody) in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.
5/8/25- Completed pre-IND meeting. 8/11/25- IND filing in Q4 2025. 11/4/25- Present preclinical data at SITC'25 on November 7, 2025. 11/05/25:- IND filing remains on track for Q4 2025; initial Ph1 clinical data expected in H2 2026. 03/05/26:- IND cleared; Ph1 study to open for enrollment in Q1 2026; initial clinical data expected H2 2026. 05/05/26:- Phase 1 study initiated in solid tumors; initial CTX-10726 clinical data expected Q4 2026. 08/06/26:- First patients dosed; Ph1 actively enrolling; initial clinical data expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.